Andrew Aromando is a C-level executive and strategic advisor to high-growth life sciences companies and top-tier private equity firms, leveraging his 30+ years of pharmaceutical and biotech industry experience in multidisciplinary roles.
He has built long-term, trusted partnerships with clients and colleagues through proven leadership and the development of clinical and commercial strategies and tactics in successful support of assets in the clinic, new product launches, and mature brands. Andrew is founder and president of The Ardu Group, a strategic life sciences advisory firm launched in 2018.
Andrew previously served as chief commercial officer of WCG Clinical, executive vice president, head of Business Development, North America at Syneos Health, vice president, Business Development at IQVIA, CEO of Cahaba Pharmaceuticals, and senior vice president, Commercial at Alfacell. He began his career in field sales at Novartis.
Andrew holds an M.A. from Rutgers University and a B.A. from The College of New Jersey.